Skip Navigation

Skip Navigation

Issue No. 9  | February 23, 2009
View HTML version

AIDSinfo.nih.gov is pleased to provide you with a weekly update of highlights about what has happened in the world of HIV/AIDS treatment, prevention, and research. We hope you find this encapsulated view of HIV/AIDS news useful.

Globe of the earth

Updated Pediatric Treatment Guidelines Now Available!

AIDSinfo is proud to announce that the latest update to the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection has been released. The new version includes the following updates:

  • What Drugs to Start: Information on darunavir has been added.
  • Antiretroviral Treatment Failure in Infants, Children, and Adolescents: The former section "Management of the Treatment-Experienced Child" has been completely revised into a more detailed section on management of treatment failure in children.
  • A detailed discussion of discordance among viral, immune, and clinical responses has been added.
  • A new table on Assessment of Antiretroviral Treatment Failure has been added.
  • Revised sections on Approach to the Management of Treatment Failure and Choice of Next Antiretroviral Regimen for Treatment Failure with Evidence of Drug Resistance have been added.
  • A new section on the Use of Antiretroviral Agents Not Approved for Use in Children has been added.
  • The Antiretroviral Drug Resistance Testing section has been updated and now includes information on tropism assays.
  • Appendix B: Characteristics of Available Antiretroviral Drugs - Updates have been added for abacavir, didanosine, lamivudine, stavudine, zidovudine, nevirapine, atazanavir, darunavir, ritonavir, and maraviroc.
  • Supplement I: Pediatric Antiretroviral Drug Information - Updates have been added to the overview, and to drug sections on abacavir, didanosine, lamivudine, zidovudine, efavirenz, darunavir, ritonavir, maraviroc, and raltegravir.

Changes to the guidelines are summarized in the "What's New in the Document?" section located at the front of the guidelines. The changes are also highlighted in yellow throughout the text and tables.

In addition to the updated content, this revision was developed using a new format in which the relevant tables and references for each section are incorporated into the body of the document. Some additional tables are in an appendix at the end of the document. A separate PDF file including all the tables can be found at the AIDSinfo Web site.

The updated guidelines are available for download from the Pediatric Guidelines section of the AIDSinfo Web site. You can also request to receive them by email from the AIDSinfo Order Publications section.


Your Feedback Is Important!

The Pediatric Antiretroviral Guidelines Working Group would like to hear your feedback on the latest revisions to the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Please send your comments with the subject line "Pediatric Comments" to AIDSinfoWebmaster@aidsinfo.nih.gov by March 9, 2009.


ClinicalTrials.gov Info

Subscribe Info

Contact AIDSinfo
Download Adobe Acrobat(R) Reader TM to view PDF files located on this site.
ISSN 1558-3228





previewPage